RELB antibody (AA 273-443)

Catalog No. ABIN7539852

This Mouse Monoclonal antibody specifically detects RELB in ELISA, IHC, FACS and ICC. It exhibits reactivity toward Human.

Quick Overview for RELB antibody (AA 273-443) (ABIN7539852)

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This RELB antibody is un-conjugated

Application: ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunocytochemistry (ICC)

Clone: 2E4B1

Product Details anti-RELB Antibody

Binding Specificity: AA 273-443

Purpose: RELB Antibody

Purification: Purified antibody

Immunogen: Purified recombinant fragment of human RELB (AA: 273-443) expressed in E. Coli.

Isotype: IgG2a

Application Details

Application Notes:

ELISA: 1/10000

FCM: 1/200 - 1/400

ICC: 1/200 - 1/1000

Restrictions: For Research Use only

Handling

Buffer: Purified antibody in PBS with 0.05 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Target Details for RELB

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Alternative Name: RELB

Background: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment

Molecular Weight: 62.1 kDa

Gene ID: 5971

UniProt: Q01201

Pathways: NF-kappaB Signaling, RTK Signaling